Hepatic Cirrhosis Clinical Trial
Official title:
Safety and Efficacy Study of Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis
The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for Hepatic Cirrhosis.
Human umbilical cord mesenchymal stem cells exhibit the potential to differentiate into
mature cells typical of several tissues, which have been confirmed in in vivo and in vitro
experiments. There have been few clinical reports describing umbilical cord mesenchymal stem
cells for treatment of Hepatic Cirrhosis.
To investigate the effects of hUC-MSC treatment for Hepatic Cirrhosis, 20 patients with
Hepatic Cirrhosis will be enrolled and receive 4 times of hUC-MSC transplantation.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01349348 -
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
|
Phase 3 | |
| Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
| Recruiting |
NCT05904470 -
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
|
Phase 2 | |
| Completed |
NCT02138253 -
A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
|
Phase 2 | |
| Completed |
NCT00794482 -
Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.
|
Phase 3 | |
| Completed |
NCT00856713 -
Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02163512 -
Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites
|
||
| Completed |
NCT00857480 -
Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin
|
Phase 1 | |
| Completed |
NCT00006164 -
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
|
Phase 3 | |
| Completed |
NCT03486912 -
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
|
Phase 2 | |
| Completed |
NCT00698464 -
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
|
Phase 1 | |
| Completed |
NCT02778425 -
The Treatment of Hepatocirrhosis and Portal Hypertension
|
N/A | |
| Completed |
NCT03445208 -
A Study of Experimental Medication BMS-986036 Given to Healthy Participants
|
Phase 1 | |
| Completed |
NCT03420768 -
A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C
|
Phase 2 | |
| Completed |
NCT03804593 -
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)
|
||
| Completed |
NCT03712280 -
MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)
|
Phase 2 | |
| Completed |
NCT02230683 -
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
|
Phase 2 | |
| Completed |
NCT02230670 -
A Study of IDN-6556 in Subjects With Liver Cirrhosis
|
Phase 2 | |
| Completed |
NCT01135628 -
Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy
|
N/A | |
| Completed |
NCT00856869 -
Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers
|
Phase 1/Phase 2 |